MedTrace Logo

A Study on the Treatment of Parkinson's Disease With Autologous Neural Stem Cells

NCT03815071 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2019-01-31

No results posted yet for this study

Summary

This is a single center, single arm and open-label study to investigate the safety and efficacy of iPS-NCS with Parkinson's Disease

Conditions

  • Parkinson Disease

Interventions

DRUG

Ips-nsc cells

Total dose of ips-nsc cells will be administered at day0.

Sponsors & Collaborators

  • The First People's Hospital of Yunnan Province/First People's Hospital of Yunan Provinve New Kunhua Hospital

    collaborator UNKNOWN

  • Henan Provincial People's Hospital

    collaborator OTHER

  • Beijing Hospital

    collaborator OTHER_GOV

  • Allife Medical Science and Technology Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-01
Primary Completion
2020-02-01
Completion
2021-02-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03815071 on ClinicalTrials.gov